Jul. 7 at 3:38 PM
Jefferies⬆️
$COGT PT to
$28 from
$23, reitd Buy and said it thinks the pivotal SUMMIT data hit the home run scenario - SURVEY suggests
$1B oppy for bezu in ISM alone - sees read-across to ASM & GIST (
$1.3B TAM).
$BPMC -
$SNY
$GSK $NVS
Leerink⬆️
$COGT Pt to
$18 from
$16, reitd OP, +⬆️Bezu' PoS in ISM to
$75% from 50% after Bezu' data was slightly above the "home run" scenario - +said, "Despite enrolling a more severe population in SUMMIT, bezu's 8.91- point benefit is ~57% better than
$BPMC's (MP) Ayvakit, which had a 5.7-point pbo-adjusted improvement at the 25mg dose. Comparisons to Ayva are complicated by: >30% of patients in the real world escalate to 50mg of Ayva, the different TSS scales for BPMC/COGT (MS2D2 for COGT and ISM-SAF for BPMC), and SUMMIT had more severe patients, including patients with smoldering disease (~7%) and prior KIT exposure (~12%)."
In total, it models
$2.5B for peak bezu revs, w/
ISM =
$800M + ASM/GIST =
$700M/
$1B.
Jefferies & Leerink said in its notes:
